Related Experiment Video

Updated: Oct 4, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.2K

Stabilization of the RAS:PDE6D Complex Is a Novel Strategy to Inhibit RAS Signaling

Tamas Yelland1, Esther Garcia1, Charles Parry2

  • 1CRUK Beatson Institute, Glasgow G61 1BD, United Kingdom.

Journal of Medicinal Chemistry
|February 2, 2022
PubMed

Insights

Researchers developed a new strategy to target RAS (Rat Sarcoma oncogene) proteins by stabilizing their interaction with PDE6D, a prenyl-binding protein. This approach disrupts RAS localization, inhibiting cancer signaling pathways and offering a new avenue for anticancer drug development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • RAS proteins are crucial for cell signaling and are major anticancer drug targets.
  • RAS requires membrane localization for activation, but direct inhibition is challenging.
  • Disrupting RAS localization offers a novel therapeutic strategy.

Purpose of the Study:

  • To develop a novel strategy for targeting RAS by stabilizing its interaction with PDE6D.
  • To inhibit oncogenic RAS/ERK signaling by disrupting RAS localization.
  • To lay the foundation for developing small-molecule RAS:PDE6D complex stabilizers as anticancer agents.

Main Methods:

  • Rational design of RAS point mutations to stabilize the RAS:PDE6D complex.
  • Surface Plasmon Resonance (SPR) fragment screening to identify binding fragments.
  • Cocrystal structure analysis to confirm binding at the KRAS:PDE6D interface.

Main Results:

  • Engineered RAS mutations increased affinity for PDE6D, stabilizing the complex.
  • Stabilized RAS:PDE6D complexes were redirected to the cytoplasm and primary cilium.
  • Oncogenic RAS/ERK signaling was inhibited.
  • SPR screening identified fragments binding the KRAS:PDE6D interface.
  • KRAS:PDE6D stoichiometric ratios vary across cell lines, indicating potential cell-type-dependent effects.

Conclusions:

  • Stabilizing the RAS:PDE6D complex is a viable strategy for inhibiting oncogenic RAS signaling.
  • This approach offers a new foundation for developing anticancer therapeutics.
  • The cell-type-specific impact of this strategy warrants further investigation.

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.1K
Spatio-Temporal Manipulation of Small GTPase Activity at Subcellular Level and on Timescale of Seconds in Living Cells10:27

Spatio-Temporal Manipulation of Small GTPase Activity at Subcellular Level and on Timescale of Seconds in Living Cells

Published on: March 9, 2012

10.9K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.5K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.3K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.5K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
12.1K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K